m a c h i n e r e a d a b l e s e c u r i t y（m c h i n e r e d b l e s e c u r t y）.doc

下载文档 降价啦

2
0
约1.38万字
约 6页
2017-01-18 发布于湖南
举报
版权申诉
保障服务

m a c h i n e r e a d a b l e s e c u r i t y（m c h i n e r e d b l e s e c u r t y）.doc

1、本文档共6页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。

m a c h i n e r e a d a b l e s e c u r i t y（m c h i n e r e d b l e s e c u r t y）

MACHINE READABLE SECURITY FOR PHARMACEUTICALS TSSI Rutland House Hargreaves Road Groundwell Industrial Estate Swindon SN25 5AZ MACHINE READABLE SECURITY FOR PHARMACEUTICALS Executive Summary Recent developments in the availability of high quality and low cost digital scanners and printers has put the traditional approaches to protecting brands against counterfeit and fraud under threat. Visual recognition is an essential part of a brand identity but can no longer be relied on as a means of preventing counterfeit. Todays environment of legislative and social pressures together with brand owners protecting their revenues is driving the need for more sophisticated approaches to the protection of brands. Over many years Structured Magnetics solutions have provided very cost effective protection for organisations in some of the most fraud prone territories in the world, directly preventing loss of revenue and maintaining security. This white paper will explain how structured magnetics solutions can be readily implemented within the pharmaceutical industry to protect against counterfeit, identify parallel or gray market trading and provide brand owner and customer assurance without major impact on manufacturing processes. Introduction A number of major threats are faced by the pharmaceutical industry – these include: The threat from counterfeit products causing irreparable damage to the company through: loss of sales of genuine product, loss of confidence in the drug, litigation damages awarded through negligence to adequately protect the product. Loss of revenues from illegal gray market trading, particularly with the new agreements for the low cost production of generic drugs in economically disadvantaged countries. Inability to meet the legislative requirements of auditable distribution. To date the industry has relied on visual features to protect drugs, including branding, backed up by Trade Mark and copyright prosecutions, secur